



US009113896B2

(12) **United States Patent**  
**Mulier et al.**

(10) **Patent No.:** **US 9,113,896 B2**  
(45) **Date of Patent:** **Aug. 25, 2015**

(54) **METHOD AND APPARATUS FOR CREATING A BI-POLAR VIRTUAL ELECTRODE USED FOR THE ABLATION OF TISSUE**

(75) Inventors: **Peter M. J. Mulier**, Stillwater, MN (US); **Michael F. Hoey**, Shoreview, MN (US)

(73) Assignee: **MEDTRONIC, INC.**, Minneapolis, MN (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1702 days.

(21) Appl. No.: **11/966,769**

(22) Filed: **Dec. 28, 2007**

(65) **Prior Publication Data**

US 2008/0103497 A1 May 1, 2008

**Related U.S. Application Data**

(63) Continuation of application No. 11/636,331, filed on Dec. 8, 2006, now abandoned, which is a continuation of application No. 11/229,414, filed on Sep. 16, 2005, now Pat. No. 7,156,845, which is a continuation of

(Continued)

(51) **Int. Cl.**

**A61B 18/14** (2006.01)

**A61B 18/00** (2006.01)

**A61B 18/12** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61B 18/14** (2013.01); **A61B 18/1482** (2013.01); **A61B 2018/00005** (2013.01); **A61B 2018/00053** (2013.01); **A61B 2018/00291** (2013.01); **A61B 2018/00642** (2013.01); **A61B 2018/00702** (2013.01); **A61B 2018/00791** (2013.01); **A61B 2018/00875** (2013.01);

(Continued)

(58) **Field of Classification Search**

USPC ..... 606/41  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

2,275,167 A \* 3/1942 Bierman ..... 606/42  
3,736,936 A 6/1973 Basilius et al.

(Continued)

**OTHER PUBLICATIONS**

Chitwood, "Will C. Sealy, MD: The Father of Arrhythmia Surgery—The Story of the Fisherman with a Fast Pulse," *Annals of Thoracic Surgery* 58:1228-1239, 1994.

(Continued)


*Primary Examiner* — Lee S Cohen

(74) *Attorney, Agent, or Firm* — Jeffrey J. Hohenshell

(57) **ABSTRACT**

A method and apparatus for creating a virtual electrode to ablate bodily tissue. The apparatus includes an outer tube, a first electrode, an inner tube and a second electrode. The outer tube is fluidly connected to a source of conductive fluid and defines a proximal end and a distal end. The distal end includes an opening for delivering conductive fluid from the outer tube. The first electrode is disposed at the distal end of the outer tube for applying a current to conductive fluid delivered from the outer tube. The inner tube is coaxially received within the outer tube and is connected to a source of conductive fluid. The inner tube defines a proximal end and a distal end, with the distal end forming an opening for delivering conductive fluid from the inner tube. Finally, the second electrode is disposed at the distal end of the inner tube for applying a current to conductive fluid delivered from the inner tube. With this configuration, upon final assembly, the distal end of the outer tube is axially spaced from the distal end of the inner tube such that the first electrode is spaced from the second electrode. As a result, a bi-polar virtual electrode can be established.

**11 Claims, 3 Drawing Sheets**



**Related U.S. Application Data**

application No. 10/754,768, filed on Jan. 8, 2004, now Pat. No. 6,962,589, which is a continuation of application No. 09/865,591, filed on May 25, 2001, now Pat. No. 6,706,039, which is a continuation of application No. 09/347,971, filed on Jul. 6, 1999, now Pat. No. 6,238,393.

(60) Provisional application No. 60/091,929, filed on Jul. 7, 1998.

**(52) U.S. Cl.**

CPC ... *A61B2018/126* (2013.01); *A61B 2018/1472* (2013.01); *A61B 2218/002* (2013.01); *A61B 2218/007* (2013.01)

**(56) References Cited**

## U.S. PATENT DOCUMENTS

3,807,403	A	4/1974	Stumpf et al.	5,263,493	A	11/1993	Avitall
3,823,575	A	7/1974	Parel	5,269,291	A	12/1993	Carter
3,823,718	A	7/1974	Tromovitch	5,275,595	A	1/1994	Dobak, III
3,827,436	A	8/1974	Stumpf et al.	5,277,201	A	1/1994	Stern
3,830,239	A	8/1974	Stumpf	5,281,213	A	1/1994	Milder et al.
3,859,986	A	1/1975	Okada et al.	5,281,215	A	1/1994	Milder
3,862,627	A	1/1975	Hans, Sr.	5,295,484	A	3/1994	Marcus et al.
3,886,945	A	6/1975	Stumpf et al.	5,309,896	A	5/1994	Moll et al.
3,907,339	A	9/1975	Stumpf et al.	5,316,000	A	5/1994	Chapelon et al.
3,910,277	A	10/1975	Zimmer	5,317,878	A	6/1994	Bradshaw et al.
3,913,581	A	10/1975	Ritson et al.	5,318,525	A	6/1994	West et al.
3,924,628	A	12/1975	Droegemueller et al.	5,322,520	A	6/1994	Milder
4,018,227	A	4/1977	Wallach	5,323,781	A	6/1994	Ideker et al.
4,022,215	A	5/1977	Benson	5,324,255	A	6/1994	Passafaro et al.
4,061,135	A	12/1977	Widran et al.	5,324,284	A	6/1994	Imran
4,063,560	A	12/1977	Thomas et al.	5,324,286	A	6/1994	Fowler
4,072,152	A	2/1978	Linehan	5,334,181	A	8/1994	Rubinsky et al.
4,082,096	A	4/1978	Benson	5,334,193	A	8/1994	Nardella
4,207,897	A	6/1980	Lloyd et al.	5,348,554	A	9/1994	Imran et al.
4,248,224	A	2/1981	Jones	5,353,783	A	10/1994	Nakao et al.
4,275,734	A	6/1981	Mitchiner	5,354,258	A	10/1994	Dory
4,278,090	A	7/1981	van Gerven	5,361,752	A	11/1994	Moll et al.
4,377,168	A	3/1983	Rzasa et al.	5,385,148	A	1/1995	Lesh et al.
4,519,389	A	5/1985	Gudkin et al.	5,396,887	A	3/1995	Imran
4,598,698	A	7/1986	Siegmund	5,397,304	A	3/1995	Truckai
4,601,290	A	7/1986	Effron et al.	5,400,770	A	3/1995	Nakao et al.
4,664,110	A	5/1987	Schanzlin	5,400,783	A	3/1995	Pomeranz et al.
4,736,749	A	4/1988	Lundback	5,403,309	A	4/1995	Coleman et al.
4,779,611	A	10/1988	Grooters et al.	5,403,311	A	4/1995	Abele et al.
4,802,475	A	2/1989	Weshahy	5,405,376	A	4/1995	Mulier et al.
4,815,470	A	3/1989	Curtis et al.	5,409,483	A	4/1995	Campbell et al.
4,832,048	A *	5/1989	Cohen	5,423,807	A	6/1995	Milder
4,872,346	A	10/1989	Kelly-Fry et al.	5,423,811	A	6/1995	Imran et al.
4,916,922	A	4/1990	Mullens	5,427,119	A	6/1995	Swartz et al.
4,917,095	A	4/1990	Fry et al.	5,431,649	A	7/1995	Mulier et al.
4,936,281	A	6/1990	Stasz	5,433,708	A	7/1995	Nichols et al.
4,946,460	A	8/1990	Merry et al.	5,435,308	A	7/1995	Gallup et al.
4,976,711	A	12/1990	Parins et al.	5,437,651	A	8/1995	Todd et al.
5,013,312	A	5/1991	Parins et al.	5,443,463	A	8/1995	Stern et al.
5,029,574	A	7/1991	Shimamura et al.	5,443,470	A	8/1995	Stern et al.
5,044,165	A	9/1991	Linner et al.	5,450,843	A	9/1995	Moll et al.
5,078,713	A	1/1992	Varney	5,452,582	A	9/1995	Longsworth
5,080,102	A	1/1992	Dory	5,452,733	A	9/1995	Sterman et al.
5,080,660	A	1/1992	Buelina	5,458,596	A	10/1995	Lax et al.
5,100,388	A	3/1992	Behl et al.	5,458,597	A	10/1995	Edwards et al.
5,108,390	A	4/1992	Potocky et al.	5,462,545	A	10/1995	Wang et al.
5,147,355	A	9/1992	Freidman et al.	5,465,717	A	11/1995	Imran et al.
5,178,133	A	1/1993	Pena	5,469,853	A	11/1995	Law et al.
5,197,963	A *	3/1993	Parins	5,472,876	A	12/1995	Fahy
5,207,674	A	5/1993	Hamilton	5,478,309	A	12/1995	Sweezer et al.
5,217,860	A	6/1993	Fahy et al.	5,478,330	A	12/1995	Imran et al.
5,222,501	A	6/1993	Ideker et al.	5,486,193	A	1/1996	Bourne et al.
5,224,943	A	7/1993	Goddard	5,487,385	A	1/1996	Avitall
5,228,923	A	7/1993	Hed	5,487,757	A	1/1996	Truckai et al.
5,231,995	A	8/1993	Desai	5,496,312	A	3/1996	Klicek
5,232,516	A	8/1993	Hed	5,497,774	A	3/1996	Swartz et al.
5,254,116	A	10/1993	Baust et al.	5,498,248	A	3/1996	Milder
				5,500,012	A	3/1996	Brucker et al.
				5,505,730	A	4/1996	Edwards
				5,516,505	A	5/1996	McDow
				5,520,682	A	5/1996	Baust et al.
				5,522,870	A	6/1996	Ben-Zion
				5,536,267	A	7/1996	Edwards et al.
				5,542,928	A	8/1996	Evans et al.
				5,545,195	A	8/1996	Lennox et al.
				5,545,200	A	8/1996	West et al.
				5,549,661	A	8/1996	Kordis et al.
				5,555,883	A	9/1996	Avitall
				5,558,671	A	9/1996	Yates
				5,560,362	A	10/1996	Sliwa, Jr. et al.
				5,562,720	A	10/1996	Stern et al.
				5,569,241	A	10/1996	Edwards
				5,571,088	A	11/1996	Lennox et al.
				5,571,215	A	11/1996	Sterman et al.
				5,573,532	A	11/1996	Chang et al.
				5,575,766	A	11/1996	Swartz et al.
				5,575,788	A	11/1996	Baker et al.
				5,575,810	A	11/1996	Swanson et al.
				5,578,007	A	11/1996	Imran

(56)

## References Cited

## U.S. PATENT DOCUMENTS

5,582,609	A	12/1996	Swanson et al.	5,882,346	A	3/1999	Pomeranz et al.
5,584,872	A	12/1996	LaFontaine et al.	5,885,278	A	3/1999	Fleischman
5,588,432	A	12/1996	Crowley	5,888,198	A	3/1999	Eggers et al.
5,590,657	A	1/1997	Cain et al.	5,891,095	A	4/1999	Eggers et al.
5,595,183	A	1/1997	Swanson et al.	5,893,848	A	4/1999	Negus et al.
5,607,462	A	3/1997	Imran	5,895,417	A	4/1999	Pomeranz et al.
5,609,151	A	3/1997	Mulier	5,897,553	A	4/1999	Mulier
5,617,854	A	4/1997	Munsif	5,897,554	A	4/1999	Chia et al.
5,630,837	A	5/1997	Crowley	5,899,898	A	5/1999	Arless et al.
5,637,090	A	6/1997	McGee et al.	5,899,899	A	5/1999	Arless et al.
5,643,197	A	7/1997	Brucker et al.	5,902,289	A	5/1999	Swartz et al.
5,653,692	A	8/1997	Masterson et al.	5,902,328	A	5/1999	LaFontaine et al.
5,656,029	A	8/1997	Imran et al.	5,904,711	A	5/1999	Flom et al.
5,658,278	A	8/1997	Imran et al.	5,906,580	A	5/1999	Kline-Schoder et al.
5,671,747	A	9/1997	Connor	5,906,587	A	5/1999	Zimmon
5,673,695	A	10/1997	McGee et al.	5,906,606	A	5/1999	Chee et al.
5,676,662	A	10/1997	Fleischhacker et al.	5,906,613	A	5/1999	Mulier et al.
5,676,692	A	10/1997	Sanghvi et al.	5,908,029	A	6/1999	Knudson et al.
5,676,693	A	10/1997	Lafontaine	5,913,854	A	6/1999	Maguire et al.
5,678,550	A	10/1997	Bassen et al.	5,916,213	A	6/1999	Haissaguerre et al.
5,680,860	A	10/1997	Imran	5,916,214	A	6/1999	Cosio et al.
5,681,278	A	10/1997	Igo et al.	5,921,924	A	7/1999	Avitall
5,681,308	A	10/1997	Edwards et al.	5,921,982	A	7/1999	Lesh et al.
5,683,384	A	11/1997	Gough et al.	5,927,284	A	7/1999	Borst et al.
5,687,723	A	11/1997	Avitall	5,928,191	A	7/1999	Houser et al.
5,687,737	A	11/1997	Branham et al.	5,931,810	A	8/1999	Grabek
5,688,267	A	11/1997	Panescu et al.	5,931,848	A	8/1999	Saadat
5,690,611	A	11/1997	Swartz et al.	5,954,661	A	9/1999	Greenspon et al.
5,697,281	A	12/1997	Eggers et al.	5,971,980	A	10/1999	Sherman
5,697,536	A	12/1997	Eggers et al.	5,971,983	A	10/1999	Lesh
5,697,882	A	12/1997	Eggers et al.	5,993,447	A	11/1999	Blewett et al.
5,697,909	A	12/1997	Eggers et al.	6,007,499	A	12/1999	Martin et al.
5,697,925	A	12/1997	Taylor	6,012,457	A	1/2000	Lesh
5,697,927	A	12/1997	Imran et al.	6,016,811	A	1/2000	Knopp et al.
5,697,928	A	12/1997	Walcott et al.	6,033,403	A *	3/2000	Tu et al. .... 606/41
5,713,942	A	2/1998	Stern	6,042,556	A	3/2000	Beach et al.
5,716,389	A	2/1998	Walinsky et al.	6,063,081	A	5/2000	Mulier et al.
5,718,241	A	2/1998	Ben-Haim et al.	6,071,279	A	6/2000	Whayne et al.
5,718,701	A	2/1998	Shai et al.	6,071,280	A	6/2000	Edwards et al.
5,720,775	A	2/1998	Lanard	6,088,894	A	7/2000	Oakley
5,722,402	A	3/1998	Swanson et al.	6,096,037	A	8/2000	Mulier
5,725,524	A	3/1998	Mulier et al.	6,113,592	A	9/2000	Taylor
5,730,074	A	3/1998	Peter	6,117,101	A	9/2000	Diederich et al.
5,730,127	A	3/1998	Avitall	6,120,496	A	9/2000	Whayne et al.
5,730,704	A	3/1998	Avitall	6,142,993	A	11/2000	Whayne et al.
5,733,280	A	3/1998	Avitall	6,142,994	A	11/2000	Swanson et al.
5,735,280	A	4/1998	Sherman et al.	6,152,920	A	11/2000	Thompson et al.
5,735,290	A	4/1998	Sterman et al.	6,161,543	A	12/2000	Cox et al.
5,755,760	A	5/1998	Maguire et al.	6,165,174	A	12/2000	Jacobs et al.
5,769,846	A	6/1998	Edwards et al.	6,179,824	B1	1/2001	Eggers et al.
5,782,828	A	7/1998	Chen et al.	6,217,528	B1	4/2001	Koblish et al.
5,785,706	A	7/1998	Bednarek	6,217,576	B1	4/2001	Tu et al.
5,788,636	A	8/1998	Curley	6,224,592	B1	5/2001	Eggers et al.
5,792,140	A	8/1998	Tu et al.	6,231,518	B1	5/2001	Grabek et al.
5,797,960	A	8/1998	Stevens et al.	6,235,024	B1	5/2001	Tu
5,800,428	A	9/1998	Nelson et al.	6,237,605	B1	5/2001	Vaska et al.
5,800,482	A	9/1998	Pomeranz et al.	6,238,347	B1	5/2001	Nix et al.
5,807,395	A	9/1998	Mulier et al.	6,238,393	B1	5/2001	Mulier
5,810,802	A	9/1998	Panescu et al.	6,245,061	B1	6/2001	Panescu et al.
5,827,216	A	10/1998	Igo et al.	6,245,064	B1	6/2001	Lesh et al.
5,836,947	A	11/1998	Fleischman et al.	6,245,065	B1	6/2001	Panescu et al.
5,840,030	A	11/1998	Ferek-Petric et al.	6,251,092	B1	6/2001	Qin et al.
5,844,349	A	12/1998	Oakley et al.	6,251,128	B1	6/2001	Knopp et al.
5,846,187	A	12/1998	Wells et al.	6,270,471	B1	8/2001	Hechel et al.
5,846,191	A	12/1998	Wells et al.	6,293,943	B1	9/2001	Panescu et al.
5,849,028	A	12/1998	Chen	6,296,619	B1	10/2001	Briskin et al.
5,860,974	A	1/1999	Abele	6,302,880	B1	10/2001	Schaer
5,871,523	A	2/1999	Fleischman et al.	6,311,692	B1	11/2001	Vaska et al.
5,871,525	A	2/1999	Edwards et al.	6,312,383	B1	11/2001	Lizzi et al.
5,873,845	A	2/1999	Cline et al.	6,314,962	B1	11/2001	Vaska et al.
5,876,398	A	3/1999	Mulier et al.	6,314,963	B1	11/2001	Vaska et al.
5,876,399	A	3/1999	Chia et al.	6,325,797	B1	12/2001	Stewart et al.
5,879,295	A	3/1999	Li et al.	6,327,505	B1	12/2001	Medhkour et al.
5,879,296	A	3/1999	Ockuly et al.	6,328,736	B1	12/2001	Mulier
5,881,732	A	3/1999	Sung et al.	6,332,881	B1	12/2001	Carner et al.
				6,358,248	B1	3/2002	Mulier
				6,361,531	B1	3/2002	Hissong
				6,364,876	B1	4/2002	Erb et al.
				6,368,275	B1	4/2002	Sliwa et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

6,371,955	B1	4/2002	Fuimaono et al.
6,383,151	B1	5/2002	Diederich et al.
6,385,472	B1	5/2002	Hall et al.
6,398,792	B1	6/2002	O'Connor
6,409,722	B1	6/2002	Hoey
6,413,254	B1	7/2002	Hissong et al.
6,419,648	B1	7/2002	Vitek et al.
6,425,867	B1	7/2002	Vaezy et al.
6,430,426	B2	8/2002	Avitall
6,440,130	B1	8/2002	Mulier
6,443,952	B1	9/2002	Mulier et al.
6,447,507	B1	9/2002	Bednarek et al.
6,461,314	B1	10/2002	Pant et al.
6,461,356	B1	10/2002	Patterson
6,464,700	B1	10/2002	Koblish et al.
6,471,697	B1	10/2002	Lesh
6,471,698	B1	10/2002	Edwards et al.
6,474,340	B1	11/2002	Vaska et al.
6,475,216	B2	11/2002	Mulier
6,477,396	B1	11/2002	Mest et al.
6,484,727	B1	11/2002	Vaska et al.
6,488,680	B1	12/2002	Francischelli
6,502,575	B1	1/2003	Jacobs et al.
6,514,250	B1	2/2003	Jahns
6,527,767	B2	3/2003	Wang et al.
6,537,248	B2	3/2003	Mulier
6,537,272	B2	3/2003	Christopherson et al.
6,558,382	B2	5/2003	Jahns
6,584,360	B2	6/2003	Francischelli
C15697536		6/2003	Eggers et al.
6,585,732	B2	7/2003	Mulier
6,605,084	B2	8/2003	Acker et al.
6,610,055	B1	8/2003	Swanson et al.
6,610,060	B2	8/2003	Mulier
6,613,048	B2	9/2003	Mulier
6,645,199	B1	11/2003	Jenkins et al.
6,648,883	B2	11/2003	Francischelli
6,656,175	B2	12/2003	Francischelli
6,663,627	B2	12/2003	Francischelli
6,692,450	B1	2/2004	Coleman
6,699,240	B2	3/2004	Francischelli
6,702,811	B2	3/2004	Stewart et al.
6,706,038	B2	3/2004	Francischelli
6,706,039	B2	3/2004	Mulier
6,716,211	B2	4/2004	Mulier
6,736,810	B2	5/2004	Hoey
6,755,827	B2	6/2004	Mulier
6,764,487	B2	7/2004	Mulier
6,773,433	B2	8/2004	Stewart et al.
6,776,780	B2	8/2004	Mulier
6,807,968	B2	10/2004	Francischelli
6,827,715	B2	12/2004	Francischelli
6,849,073	B2	2/2005	Hoey
6,858,028	B2	2/2005	Mulier
6,887,238	B2	5/2005	Jahns et al.
6,899,711	B2	5/2005	Stewart et al.
6,911,019	B2	6/2005	Mulier
6,916,318	B2	7/2005	Francischelli
6,936,046	B2	8/2005	Hissong
6,949,097	B2	9/2005	Stewart et al.
6,949,098	B2	9/2005	Mulier
6,960,205	B2	11/2005	Jahns
6,962,589	B2	11/2005	Mulier et al.
7,156,845	B2*	1/2007	Mulier et al. .... 606/41
2003/0045872	A1	3/2003	Jacobs
2003/0144656	A1	7/2003	Ocel
2003/0191462	A1	10/2003	Jacobs
2003/0216724	A1	11/2003	Jahns
2004/0015106	A1	1/2004	Coleman
2004/0015219	A1	1/2004	Francischelli
2004/0044340	A1	3/2004	Francischelli
2004/0049179	A1	3/2004	Francischelli
2004/0078069	A1	4/2004	Francischelli
2004/0082948	A1	4/2004	Stewart et al.
2004/0087940	A1	5/2004	Jahns

2004/0092926	A1	5/2004	Hoey
2004/0138621	A1	7/2004	Jahns
2004/0138656	A1	7/2004	Francischelli
2004/0143260	A1	7/2004	Francischelli
2004/0186465	A1	9/2004	Francischelli
2004/0215183	A1	10/2004	Hoey
2004/0220560	A1	11/2004	Briscoe
2004/0236322	A1	11/2004	Mulier
2004/0267326	A1	12/2004	Ocel
2005/0010095	A1	1/2005	Stewart
2005/0033280	A1	2/2005	Francischelli
2005/0090815	A1	4/2005	Francischelli
2005/0143729	A1	6/2005	Francischelli
2005/0165392	A1	7/2005	Francischelli
2005/0209564	A1	9/2005	Bonner
2005/0267454	A1	12/2005	Hissong
2006/0009756	A1	1/2006	Francischelli
2006/0009759	A1	1/2006	Christian

## OTHER PUBLICATIONS

Gallagher et al., "Cryosurgical Ablation of Accessory Atrioventricular Connections: A Method for Correction of the Pre-excitation Syndrome," *Circulation* 55(3): 471-479, 1977.

Sealy, "Direct Surgical Treatment of Arrhythmias: The Last Frontier in Surgical Cardiology," *Chest* 75(5): 536-537, 1979.

Sealy, "The Evolution of the Surgical Methods for Interruption of Right Free Wall Kent Bundles," *The Annals of Thoracic Surgery* 36(1): 29-36, 1983.

Guiraudon et al., "Surgical Repair of Wolff-Parkinson-White Syndrome: A New Closed-Heart Technique," *The Annals of Thoracic Surgery* 37(1): 67-71, 1984.

Klein et al., "Surgical Correction of the Wolff-Parkinson-White Syndrome in the Closed Heart Using Cryosurgery: A Simplified Approach," *JACC* 3(2): 405-409, 1984.

Randall et al., "Local Epicardial Chemical Ablation of Vagal Input to Sino-Atrial and Atrioventricular Regions of the Canine Heart," *Journal of the Autonomic Nervous System* 11:145-159, 1984.

Guiraudon et al., "Surgical Ablation of Posterior Septal Accessory Pathways in the Wolf-Parkinson-White Syndrome by a Closed Heart Technique," *Journal Thoracic Cardiovascular Surgery* 92:406-413, 1986.

Gallagher et al., "Surgical Treatment of Arrhythmias," *The American Journal of Cardiology* 61:27A-44A, 1988.

Mahomed et al., "Surgical Division of Wolff-Parkinson-White Pathways Utilizing the Closed-Heart Technique: A 2-Year Experience in 47 Patients," *The Annals of Thoracic Surgery* 45(5): 495-504, 1988.

Cox et al., *Surgery for Atrial Fibrillation; Seminars in Thoracic and Cardiovascular Surgery*, vol. 1, No. 1 (Jul. 1989) pp. 67-73.

Bredikis and Bredikis; *Surgery of Tachyarrhythmia: Intracardiac Closed Heart Cryoablation; PACE*, vol. 13, pp. 1980-1984.

McCarthy et al., "Combined Treatment of Mitral Regurgitation and Atrial Fibrillation with Valvuloplasty and the Maze Procedure," *The American Journal of Cardiology* 71: 483-486, 1993.

Yamauchi et al. "Use of Intraoperative Mapping to Optimize Surgical Ablation of Atrial Flutter," *The Annals of Thoracic Surgery* 56: 337-342, 1993.

Graffigna et al., "Surgical Treatment of Wolff-Parkinson-White Syndrome: Epicardial Approach Without the Use of Cardiopulmonary Bypass," *Journal of Cardiac Surgery* 8: 108-116, 1993.

Siefert et al., "Radiofrequency Maze Ablation for Atrial Fibrillation," *Circulation* 90(4): 1-594.

Surgical treatment of atrial fibrillation: a review; *Europace* (2004) 5, S20-S29.

Elvan et al., "Radiofrequency Catheter Ablation of the Atria Reduces Inducibility and Duration of Atrial Fibrillation in Dog," *Circulation* 91: 2235-2244, 1995.

Cox et al., "Modification of the Maze Procedure for Atrial Flutter and Atrial Fibrillation. I. Rational and Surgical Results," *The Journal of Thoracic Cardiovascular Surgery* 110: 473-484, 1995.

Cox, "The Maze III Procedure for Treatment of Atrial Fibrillation," Sabiston DC, ed *Atlas of Cardiothoracic Surgery*, Philadelphia: WB Saunders: 460-475, 1994.

(56)

**References Cited****OTHER PUBLICATIONS**

Sueda et al., "Simple Left Atrial Procedure for Chronic Atrial Fibrillation Associated with Mitral Valve Disease," *The Annals of Thoracic Surgery* 62(6): 1796-1800, 1996.

Tsui et al., "Maze 3 for Atrial Fibrillation: Two Cuts Too Few?" *PACE* 17: 2163-2166, 1994.

Kosakai et al., "Cox Maze Procedure for Chronic Atrial Fibrillation Associated with Mitral Valve Disease," *The Journal of Thoracic Cardiovascular Surgery* 108: 1049-1055, 1994.

Cox et al., "The Surgical Treatment of Atrial Fibrillation, IV Surgical Technique," *J of Thorac Cardiovasc Surg*, 1991: 101: 584-593.

Nardella, "Radio Frequency Energy and Impedance Feedback," *SPIE* vol. 1068, *Catheter Based Sensing and Imaging Technology* (1989).

Avitall et al., "A Thoracoscopic Approach to Ablate Atrial Fibrillation Via Linear Radiofrequency Lesion Generation on the Epicardium of Both Atria," *PACE*; Apr. 1996;19(Part II):626,#241.

Sie et al., "Radiofrequency Ablation of Atrial Fibrillation in Patients Undergoing Mitral Valve Surgery. First Experience," *Circulation* (Nov. 1996) 96:450,1-675,#3946.

Sie et al., "Radiofrequency Ablation of Atrial Fibrillation in Patients Undergoing Valve Surgery," *Circulation* (Nov. 1997) 84:1450,#2519.

Cox, "Evolving Applications of the Maze Procedure for Atrial Fibrillation," *Ann Thorac Surg*, 1993;55:578-580.

Cox et al. "Five-Year Experience with the Maze Procedure for Atrial Fibrillation," *Ann Thorac Surg*, 1993; 56:814-824.

Avitall et al., "New Monitoring Criteria for Transmural Ablation of Atrial Tissues," *Circulation*, 1996;94(Supp 1):I-493,#2889.

Cox et al., "An 8 1/2 Year Clinical Experience with Surgery for Atrial Fibrillation," *Annals of Surgery*, 1996;224(3):267-275.

Haissaguerre et al., "Radiofrequency Catheter Ablation for Paroxysmal Atrial Fibrillation in Humans: Elaboration of a procedure based on electrophysiological data," *Nonpharmacological Management of Atrial Fibrillation*, 1997 pp. 257-279.

Haissaguerre et al., "Right and Left Atrial Radiofrequency Catheter Therapy of Paroxysmal Atrial Fibrillation," *Journal of Cardiovascular Electrophysiology*, 1996;7(12):1132-1144.

Haissaguerre et al., "Role of Catheter Ablation for Atrial Fibrillation," *Current Opinion in Cardiology*, 1997;12:18-23.

Kawaguchi et al., "Risks and Benefits of Combined Maze Procedure for Atrial Fibrillation Associated with Organic Heart Disease," *JACC*, 1996;28(4):985-990.

Cox, et al., "Perinodal cryosurgery for atrioventricular node reentry tachycardia in 23 patients," *Journal of Thoracic and Cardiovascular Surgery*, 99:3, Mar. 1990, pp. 440-450.


Cox, "Anatomic-Electrophysiologic Basis for the Surgical Treatment of Refractory Ischemic Ventricular Tachycardia," *Annals of Surgery*, Aug. 1983; 198:2;119-129.


Williams, et al., "Left atrial isolation," *J Thorac Cardiovasc Surg*; 1980; 80: 373-380.

Sueda et al., "Simple Left Atrial Procedure for Chronic Atrial Fibrillation Associated with Mitral Valve Disease," *Ann Thorac Surg*, 1996;62:1796-1800.

Sueda et al., "Efficacy of a Simple Left Atrial Procedure for Chronic Atrial Fibrillation in Mitral Valve Operations," *Ann Thorac Surg*, 1997;63:1070-1075.

\* cited by examiner

*Fig. 1*






Fig. 3



# METHOD AND APPARATUS FOR CREATING A BI-POLAR VIRTUAL ELECTRODE USED FOR THE ABLATION OF TISSUE

This patent application is a continuation of U.S. patent application Ser. No. 11/636,331, filed Dec. 8, 2006, now abandoned, which is a continuation of U.S. patent application Ser. No. 11/229,414, filed Sep. 16, 2005, now U.S. Pat. No. 7,156,845, which is a continuation of U.S. patent application Ser. No. 10/754,768, filed Jan. 8, 2004, now U.S. Pat. No. 6,962,589, which is a continuation of U.S. patent application Ser. No. 09/865,591, filed May 25, 2001, now U.S. Pat. No. 6,706,039, which is a continuation of U.S. patent application Ser. No. 09/347,971, filed Jul. 6, 1999, now U.S. Pat. No. 6,238,393, which claimed the benefit of U.S. Provisional Application No. 60/091,929, filed on Jul. 7, 1998.

## FIELD OF THE INVENTION

The present invention relates generally to an apparatus for creating a virtual electrode. More particularly, the present invention relates to an apparatus for the creation of a virtual electrode that is useful for the ablation of soft tissue and neoplasms.

## BACKGROUND OF THE PRESENT INVENTION

The utilization of an electric current to produce an ameliorative effect on a bodily tissue has a long history, reportedly extending back to the ancient Greeks. The effects on bodily tissue from an applied electric current, and thus the dividing line between harmful and curative effects, will vary depending upon the voltage levels, current levels, the length of time the current is applied, and the tissue involved. One such effect resulting from the passage of an electric current through tissue is heat generation.

Body tissue, like all non-superconducting materials, conducts current with some degree of resistance. This resistance creates localized heating of the tissue through which the current is being conducted. The amount of heat generated will vary with the power  $P$  deposited in the tissue, which is a function of the product of the square of the current  $I$  and the resistance  $R$  of the tissue to the passage of the current through it ( $P=I^2R$ ).

As current is applied to tissue, then, heat is generated due to the inherent resistance of the tissue. Deleterious effects in the cells making up the tissue begin to occur at about 42° Celsius. As the temperature of the tissue increases due to heat generated by the tissue's resistance, the tissue will undergo profound changes and eventually, as the temperature becomes high enough, that is, generally greater than 45° C., the cells will die. The zone of cell death is known as a lesion and the procedure followed to create the lesion is commonly called an ablation. As the temperature increases beyond cell death temperature, complete disintegration of the cell walls and cells caused by boiling off of the tissue's water can occur. Cell death temperatures can vary somewhat with the type of tissue to which the power is being applied, but generally will begin to occur within the range of 45° to 60° C., though actual cell death of certain tissue cells may occur at a higher temperature.

In recent times, electric current has found advantageous use in surgery, with the development of a variety of surgical instruments for cutting tissue or for coagulating blood. Still more recently, the use of alternating electric current to ablate, that is, kill, various tissues has been explored. Typically, current having a frequency from about 3 kilohertz to about

300 gigahertz, which is generally known as radiofrequency or radiofrequency (RF) current, is used for this procedure. Destruction, that is, killing, of tissue using an RF current is commonly known as radiofrequency ablation. Often radiofrequency ablation is performed as a minimally invasive procedure and is thus known as radiofrequency catheter ablation because the procedure is performed through and with the use of a catheter. By way of example, radiofrequency catheter ablation has been used to ablate cardiac tissue responsible for irregular heart beats or arrhythmias.

The prior art applications of current to tissue have typically involved applying the current using a dry electrode. That is, a metal electrode is applied to the tissue desired to be affected and a generated electric current is passed through the electrode to the tissue. A commonly known example of an instrument having such an operating characteristic is an electrosurgical instrument known as a bovie knife. This instrument includes a cutting/coagulating blade electrically attached to a current generator. The blade is applied to the tissue of a patient and the current passes through the blade into the tissue and through the patient's body to a metal base electrode or ground plate usually placed underneath and in electrical contact with the patient. The base electrode is in turn electrically connected to the current generator so as to provide a complete circuit.

As the current from the bovie knife passes from the blade into the tissue, the resistance provided by the tissue creates heat. In the cutting mode, a sufficient application of power through the bovie knife to the tissue causes the fluid within the cell to turn to steam, creating a sufficient overpressure so as to burst the cell walls. The cells then dry up, desiccate, and carbonize, resulting in localized shrinking and an opening in the tissue. Alternatively, the bovie knife can be applied to bleeding vessels to heat and coagulate the blood flowing therefrom and thus stop the bleeding.

As previously noted, another use for electrical instruments in the treatment of the body is in the ablation of tissue. To expand further on the brief description given earlier of the ablation of cardiac tissue, it has long been known that a certain kind of heart tissue known as sino-atrial and atrio-ventricular nodes spontaneously generate an electrical signal that is propagated throughout the heart along conductive pathways to cause it to beat. Occasionally, certain heart tissue will misfire, causing the heart to beat irregularly. If the errant electrical pathways can be determined, the tissue pathways can be ablated and the irregular heartbeat remedied. In such a procedure, an electrode is placed via a catheter into contact with the tissue and then current is applied to the tissue via the electrode from a generator of RF current. The applied current will cause the tissue in contact with the electrode to heat. Power will continue to be applied until the tissue reaches a temperature where the heart tissue dies, thereby destroying the errant electrical pathway and the cause of the irregular heartbeat.

Another procedure using RF ablation is transurethral needle ablation, or TUNA, which is used to create a lesion in the prostate gland for the treatment of benign prostatic hyperplasia (BPH) or the enlargement of the prostate gland. In a TUNA procedure, a needle having an exposed conductive tip is inserted into the prostate gland and current is applied to the prostate gland via the needle. As noted previously, the tissue of the prostate gland heats locally surrounding the needle tip as the current passes from the needle to the base electrode. A lesion is created as the tissue heats and the destroyed cells may be reabsorbed by the body, infiltrated with scar tissue, or just become non-functional.

While there are advantages and uses for such dry electrode instruments, there are also several notable disadvantages. One of these disadvantages is that during a procedure, coagulum—dried blood cells and tissue cells—will form on the electrode engaging the tissue. Coagulum acts as an insulator and effectively functions to prevent current transfer from the blade to the tissue. This coagulum insulation can be overcome with more voltage so as to keep the current flowing, but only at the risk of arcing and injuring the patient. Thus, during surgery when the tissue is cut with an electrosurgical scalpel, a build-up of coagulated blood and desiccated tissue will occur on the blade, requiring the blade to be cleaned before further use. Typically, cleaning an electrode/scalpel used in this manner will involve simply scraping the dried tissue from the electrode/scalpel by rubbing the scalpel across an abrasive pad to remove the coagulum. This is a tedious procedure for the surgeon and the operating staff since it requires the real work of the surgery to be discontinued while the cleaning operation occurs. This procedure can be avoided with the use of specially coated blades that resist the build up of coagulum. Such specialty blades are costly, however.

A second disadvantage of the dry electrode approach is that the electrical heating of the tissue creates smoke that is now known to include cancer-causing agents. Thus, preferred uses of such equipment will include appropriate ventilation systems, which can themselves become quite elaborate and quite expensive.

A further, and perhaps the most significant, disadvantage of dry electrode electrosurgical tools is revealed during cardiac ablation procedures. During such a procedure, an electrode that is otherwise insulated but having an exposed, current carrying tip is inserted into the heart chamber and brought into contact with the inner or endocardial side of the heart wall where the ablation is to occur. The current is initiated and passes from the current generator to the needle tip electrode and from there into the tissue so that a lesion is created. Typically, however, the lesion created by a single insertion is insufficient to cure the irregular heartbeat because the lesion created is of an insufficient size to destroy the errant electrical pathway. Thus, multiple needle insertions and multiple current applications are almost always required to ablate the errant cardiac pathway, prolonging the surgery and thus increasing the potential risk to the patient.

This foregoing problem is also present in TUNA procedures, which similarly require multiple insertions of the needle electrode into the prostate gland. Failing to do so will result in the failure to create a lesion of sufficient size otherwise required for a beneficial results. As with radiofrequency catheter ablation of cardiac tissue, then, the ability to create a lesion of the necessary size to alleviate BPH symptoms is limited and thus requires multiple insertions of the electrode into the prostate.

A typical lesion created with a dry electrode using RF current and a single insertion will normally not exceed one centimeter in diameter. This small size—often too small to be of much or any therapeutic benefit—stems from the fact that the tissue surrounding the needle electrode tends to desiccate as the temperature of the tissue increases, leading to the creation of a high resistance to the further passage of current from the needle electrode into the tissue, all as previously noted with regard to the formation of coagulum on an electrosurgical scalpel. This high resistance—more properly termed impedance since typically an alternating current is being used—between the needle electrode and the base electrode is commonly measured by the RP current generator. When the measured impedance reaches a predetermined level, the generator will discontinue current generation. Dis-

continuance of the ablation procedure under these circumstances is necessary to avoid injury to the patient.

Thus, a typical procedure with a dry electrode may involve placing the needle electrode at a first desired location; energizing the electrode to ablate the tissue; continue applying current until the generator measures a high impedance and shuts down; moving the needle to a new location closely adjacent to the first location; and applying current again to the tissue through the needle electrode. This cycle of electrode placement, electrode energization, generator shut down, electrode re-emplacement, and electrode re-energization, will be continued until a lesion of the desired size has been created. As noted, this increases the length of the procedure for the patient. Additionally, multiple insertions increases the risk of at least one of the placements being in the wrong location and, consequently, the risk that healthy tissue may be undesirably affected while diseased tissue may be left untreated. The traditional RF ablation procedure of using a dry ablation therefore includes several patient risk factors that both patient and physician would prefer to reduce or eliminate.

The therapeutic advantages of RF current could be increased if a larger lesion could be created safely with a single positioning of the current-supplying electrode. A single positioning would allow the procedure to be carried out more expeditiously and more efficiently, reducing the time involved in the procedure. Larger lesions can be created in at least two ways. First, simply continuing to apply current to the patient with sufficiently increasing voltage to overcome the impedance rises will create a larger lesion, though almost always with undesirable results to the patient. Second, a larger lesion can be created if the current density, that is, the applied electrical energy, could be spread more efficiently throughout a larger volume of tissue. Spreading the current density over a larger tissue volume would correspondingly cause a larger volume of tissue to heat in the first instance. That is, by spreading the applied power throughout a larger tissue volume, the tissue would heat more uniformly over a larger volume, which would help to reduce the likelihood of generator shutdown due to high impedance conditions. The applied power, then, will cause the larger volume of tissue to be ablated safely, efficiently, and quickly.

Research conducted under the auspices of the assignee of the present invention has focused on spreading the current density throughout a larger tissue volume through the creation, maintenance, and control of a virtual electrode within or adjacent to the tissue to be ablated. A virtual electrode can be created by the introduction of a conductive fluid, such as isotonic or hypertonic saline, into or onto the tissue to be ablated. The conductive fluid will facilitate the spread of the current density substantially equally throughout the extent of the flow of the conductive fluid, thus creating an electrode—a virtual electrode—substantially equal in extent to the size of the delivered conductive fluid. RF current can then be passed through the virtual electrode into the tissue.

A virtual electrode can be substantially larger in volume than the needle tip electrode typically used in RF interstitial ablation procedures and thus can create a larger lesion than can a dry, needle tip electrode. That is, the virtual electrode spreads or conducts the RF current density outward from the RF current source—such as a current carrying needle, forceps or other current delivery device—into or onto a larger volume of tissue than is possible with instruments that rely on the use of a dry electrode. Stated otherwise, the creation of the virtual electrode enables the current to flow with reduced resistance or impedance throughout a larger volume of tissue, thus spreading the resistive heating created by the current flow

5

through a larger volume of tissue and thereby creating a larger lesion than could otherwise be created with a dry electrode.

While the efficacy of RP current ablation techniques using a virtual electrode has been demonstrated in several studies, the currently available instruments useful in such procedures lags behind the research into and development of hoped-for useful treatment modalities for the ablation of soft tissue and malignancies.

It would be desirable to have an apparatus capable of creating a virtual electrode for the controlled application of tissue ablating RF electric current to a tissue of interest so as to produce a lesion of desired size and configuration.

#### SUMMARY OF THE INVENTION

One aspect of the present invention provides a surgical apparatus for creating a virtual electrode to ablate bodily tissue. The surgical apparatus comprises an outer tube, a first electrode, an inner tube and a second electrode. The outer tube is fluidly connected to a source of conductive fluid and defines a proximal end and a distal end. In this regard, the distal end of the outer tube includes an opening for delivering a conductive fluid from the outer tube. The first electrode is disposed at the distal end of the outer tube and is configured to apply a current to conductive fluid delivered from the outer tube. The inner tube is coaxially received within the outer tube. The inner tube is fluidly connected to a source of conductive fluid and defines a proximal end and a distal end. In this regard, the distal end of the inner tube forms an opening for delivering a conductive fluid from the inner tube. The second electrode is disposed at the distal end of the inner tube. The second electrode is configured to apply a current to conductive fluid delivered from the inner tube. Upon final assembly, the distal end of the outer tube is axially spaced from the distal end of the inner tube such that the first electrode is spaced from the second electrode. With this configuration, then, a bi-polar virtual electrode can be established.

Another aspect of the present invention provides a surgical system for creating a virtual electrode to ablate bodily tissue. The surgical system includes a fluid source, a current source, and a surgical instrument. The fluid source maintains a supply of conductive fluid. The current source is configured to selectively supply an electrical current. The surgical instrument includes an outer tube, a first electrode, an inner tube and a second electrode. The outer tube is fluidly connected to the fluid source and defines a proximal end and a distal end. The distal end of the outer tube includes an opening for delivering the conductive fluid. The first electrode is disposed at the distal end of the outer tube and is electrically connected to the current source. The inner tube is coaxially received within the outer tube and is fluidly connected to the fluid source. The inner tube defines a proximal end and a distal end, with the distal end of the inner tube forming an opening for delivering the conductive fluid. The second electrode is disposed at the distal end of the inner tube and is electrically connected to the current source. Upon final assembly, the distal end of the outer tube is spaced from the distal end of the inner tube such that the conductive fluid is delivered as a first bolus from the outer tube and a second bolus from the inner tube. Current is applied to the first and second boluses by the first and second electrodes, respectively. With this configuration, a bi-polar virtual electrode can be created.

Another aspect of the present invention relates to a method for ablating bodily tissue at a target site. The method includes delivering a first bolus of a conductive fluid at the target site. A second bolus of conductive fluid is also delivered at the target site, the second bolus being spaced from the first bolus.

6

Finally, a current is substantially simultaneously applied to each of the first bolus and the second bolus to create a virtual electrode, ablating tissue in contact with the first and second boluses. In one preferred embodiment, tissue between the first and second boluses is collapsed prior to applying the current.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a block diagram of a system for creating a virtual electrode in accordance with the present invention;

FIG. 2 is a perspective view, with a portion cut away, of a surgical apparatus in accordance with the present invention; and

FIG. 3 is a schematic view of a portion of the surgical apparatus of FIG. 2 ablating bodily tissue.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

FIG. 1 illustrates in block form a system 10 for RF ablation useful with the present invention. The system 10 includes a current source of radiofrequency alternating electric current 12, a fluid source of RF ablating fluid 14, including but not limited to saline and other conductive solutions, and a surgical instrument 16 for delivering RF current and ablation fluid to a tissue site (not shown) for ablation purposes. In one preferred embodiment, the surgical instrument 16 is connected to the current source 12 and the fluid source 14. It will be understood that the current source 12 and the fluid source 14 may be combined into a single operational structure controlled by an appropriate microprocessor for a controlled delivery of ablating fluid and a controlled application of RF current, both based upon measured parameters such as but not limited to, flow rate, tissue temperature at the ablation site and at areas surrounding the ablation site; impedance, the rate of change of the impedance, the detection of arcing between the surgical instrument and the tissue, the time period during which the ablation procedure has been operating, and additional factors as desired.

While the surgical instrument 16 is shown as being connected to both the current source 12 and the fluid source 14, the present system is not so limited but could include separate needles or other instruments useful in RF liquid ablation procedures, that is, for example, a single straight or coiled needle having an exposed end and a fluid flow path there through could be used to deliver both fluid and current to the target tissue for ablation purposes. Alternatively, a separate needle could be used to deliver the current and a separate needle or needles could be used to deliver fluid to the target tissue. In addition, the application of the present system is not limited to the use of straight needles or helical needles as surgical instruments but could find use with any type of instrument wherein a conductive solution is delivered to a tissue and an RF current is applied to the tissue through the conductive fluid. Such instruments thus would include straight needles, helical needles, forceps, roller balls, instruments for the treatment of vascular disorders, and any other instrument.

In one preferred embodiment, the system 10 further includes a second fluid source 18 for delivery of tissue protecting fluid, via a delivery instrument 20, to a tissue whose ablation is not desired.

The surgical instrument 16 may assume a wide variety of forms. One preferred embodiment of a surgical apparatus 50 is shown in FIG. 2. The apparatus 50 generally includes a bi-polar electrode that is useful in an ablation procedure using

an RF ablating fluid such as, but not limited to, isotonic or hypertonic saline. Further, the apparatus 50 generally includes a plurality of coaxial thin walled tubes forming a catheter delivery system for RF ablating fluid and RF ablating current. Thus, the apparatus 50 preferably includes a first or outer thin walled tube 52 having a proximally attached hemostasis valve 54. The valve 54 includes an inlet 56 for RF ablating fluid flow as indicated by arrow 58 and also an access port 60 for an electrical line 62, which can be electrically connected to the RP current source 12 (FIG. 1). A distal end of the first tube 52 may be provided with one or more thermocouples or other temperature sensors 64. The distal end of the first tube 52 also includes an electrode 66 which is electrically connected to the line 62, thereby providing one of the two bi-polar electrodes envisioned by a preferred embodiment of the present invention. It will be understood that the first tube 52 is electrically insulated or otherwise non-conductive. The first tube 52 provides a flow passage for the RF ablating fluid from the fluid source 14 (FIG. 1) to the distal end of the first tube 52 where it exits the first tube 52 as indicated by arrows 68.

The apparatus 50 further includes a second or intermediate thin walled tube 70 coaxially disposed within the first tube 52. The second tube 70 has a proximally attached hemostasis valve 72. The valve 72 includes a suction port 74 for directing fluid flow as indicated by arrow 76. A distal end of the second tube 70 may be provided with one or more vacuum apertures 78 through which a suction is applied to surrounding tissue (not shown), via a vacuum formed at the suction port 74. Thus, applying suction to the suction port 74 will draw the surrounding tissue into contact with the vacuum apertures 78 and the distal end of the second tube 70. In addition, with this same process, some RF ablating fluid may be removed via the applied suction as indicated by arrows 80.

The apparatus 50 further includes a third or inner thin walled tube 82 coaxially disposed within the second tube 70. The third tube 82 has a proximally attached hemostasis valve 84. The valve 84 includes an inlet 84 for RF ablating fluid flow as indicated by arrow 86 and also an access port 88 for an electrical line 90, which can be electrically connected to the current source 12 (FIG. 1). A distal end of the third tube 82 also includes an electrode 92, which is electrically connected to the line 90, thereby providing the other one of the two bi-polar electrodes envisioned by a preferred embodiment of the present invention. It will be understood that the third tube 82 is electrically insulated or otherwise non-conductive. The third tube 82 provides a flow passage for the RF ablating fluid from the fluid source 14 (FIG. 1) to the distal end of the third tube 82 where it exits the third tube 82 as indicated by arrows 94.

The surgical apparatus 50 may further include a probe 100 that extends through an interior passage of the third tube 82 and that is freely movable therewithin. The probe 100 may include a thermocouple 102 disposed at a most distal end thereof and may be connected via an electrical line 104 to the RF current source 12 (FIG. 1) to provide a temperature measurement at a predetermined distance from the electrodes 66 and 92.

In operation, following delivery to a particular target site, RP ablating fluid will be provided to the ports 56 and 84 from the fluid source 14 (FIG. 1). The fluid will exit the distal ends of the first tube 52 and the third tube 82, respectively, and begin to form boluses of fluid along or within the tissue at the target site. Application of a suction at the vacuum aperture 78, via the suction port 74, will cause the tissue surrounding the distal end of the second tube 70 to be collapsed or pulled into a substantially fluid tight relationship with the second tube 70,

thereby preventing migration of the fluid, in particular via a capillary effect, along the second tube 70 between the distal ends of the first and third tubes 52, 82. RF ablating power can be applied and an ablation procedure can be carried out. By the application of suction to the tissue and the prevention of the flow of fluid along the second tube 70, shorting of the current between the electrodes 66 and 92 can be avoided.

FIG. 3 represents schematically the fluid flow and current flow achieved during use of the present invention. Thus, FIG. 3 shows a tissue 110, such as liver, into which a portion of the surgical apparatus 50 has been inserted. Infusion of the RP ablating fluid will initially create two separate boluses of fluid, 112 and 114. If not for the suction applied to the tissue surrounding vacuum apertures 78, fluid would tend to travel along the path created during insertion and placement of the apparatus 50 in the tissue 110. Applying suction intermediate the release of the fluid, however, prevents such fluid travel and substantially prevents any shortage between the electrodes 66, 92 directly therebetween. The applied current can thus spread readily through the boluses 112, 114 and then travel therebetween as indicated by the lines 116. In this way, then, ablation can be accomplished between the bi-polar electrodes 66 and 92. The lesion created with the use of such a bi-polar structure will essentially be the size of the boluses 112, 114 at a minimum, though it will be understood that cell-to-cell thermal conduction will occur that will make the lesion in reality larger than the boluses 112, 114, assuming that power is left on for the appropriate length of time.

As is well known, when an electro-surgical tool is used, or for that matter, any electrical device, a complete circuit for current flow must be provided. Thus, when a monopolar surgical instrument such as a bovie knife is used, a ground pad connected to the RF current generator is placed under the patient to provide a complete electrical circuit from the generator, to the knife, through the patient to the ground pad, and back to the generator. With the present invention, no ground pad is needed. The current flows from the current source 12 (FIG. 1) to one of the two electrodes 66 or 92 on the apparatus 50, through the patient to the other electrode 66 or 92, and then back to the current source 12. Such bi-polar structure enables the physician to localize the effect of the current passing through the patient, thereby avoiding certain risks associated with the use of a monopolar device, including but not limited to the risk of burns where the ground pad contacts the patient. Additionally, by controlling the relative spacing between the two electrodes 66, 92 of a bi-polar instrument, the size of the lesion can be controlled. Thus, where the electrodes 66, 92 are close to each other, there will be little tissue between them through which the current will travel and the lesion size will be reduced relative to an instrument where the electrodes are spaced relatively farther apart. In addition, the shape of the lesion is somewhat controllable by controlling both the fluid flow and the spacing of the electrodes 66, 92. It will be understood that regardless of the device used that the lesion size and shape is a product of many factors, including the tissue composition, the conductivity of the fluid, the amount of applied current, the amount of cell-to-cell thermal conductivity, the time period the current is applied, tissue temperature, and fluid temperature when applied, among others.

Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.

9

What is claimed is:

1. A method for ablating tissue comprising:

positioning an ablating element of an ablation device adjacent to the tissue, wherein the ablation device comprises:

an ablation member comprising an elongated tubular member, wherein the ablating element is disposed at a distal end portion of the ablation member; and

a suction member comprising an elongated tubular member having a lumen in fluid communication with a vacuum and a vacuum opening disposed at a distal end portion of the suction member, the suction member coupled to the ablation member, wherein at least a portion of the elongated tubular member of the ablation member resides within the suction member lumen and the vacuum opening;

providing suction to the tubular suction member to draw the tissue into contact with the device; and

providing an ablation energy to the ablating element for ablating the tissue.

2. The method of claim 1, wherein the ablation energy comprises electric current.

3. The method of claim 1, wherein the ablation energy comprises radiofrequency energy provided from a radiofrequency generator.

4. The method of claim 1, wherein suction is provided from a vacuum source.

5. The method of claim 1, wherein the ablating element comprises an electrode.

10

6. The method of claim 1, wherein the ablation device further comprises a temperature sensor.

7. The method of claim 6, further comprises measuring a temperature with the temperature sensor.

8. A method for ablating tissue comprising:

positioning adjacent the tissue an ablating member of an ablation device, the device comprising:

an elongated cylindrical ablation member comprising a tubular member and an ablating member disposed at a distal end portion of the ablation member; and

an elongated cylindrical suction member comprising a tubular member having a lumen in fluid communication with a vacuum and a vacuum opening disposed at a distal end portion of the suction member, the suction member coupled to the ablation member, wherein at least a portion of the ablation member passes through the lumen and the vacuum opening;

providing suction to the suction member to draw the tissue into contact with the device; and

providing an ablation energy to the ablating member for ablating the tissue.

9. The method of claim 8, wherein the ablating member comprises an electrode.

10. The method of claim 8, wherein the ablation device further comprises a temperature sensor.

11. The method of claim 10, further comprising measuring a temperature with the temperature sensor.

\* \* \* \* \*